#USA #San Francisco #Stämm #Biofabrication #High-Throughput Bioprocessor

Stämm Redefines Biomanufacturing

Stämm has made a significant leap in the field of biomanufacturing with its introduction of the High-Throughput Bioprocessor (HTB). This innovative platform is specifically designed to revolutionize the production of biologics by addressing previous limitations in infrastructure that have been a bottleneck for research and development (R&D). The HTB presents a streamlined solution, allowing for automated, single-use biofabrication tailored for both adherent and suspension cells.

Key Features of the HTB

At the heart of the HTB is the Bubble-Free Bioreactor (BFB), an advanced consumable that has been ingeniously crafted using 3D printing technology. Unlike traditional systems, it removes the need for conventional impellers, which often introduce shear forces harmful to sensitive cell populations. By employing a laminar flow mechanism akin to the capillary networks found in living tissues, the HTB provides a more nurturing environment for cells, optimizing nutrient transport and gas exchange.

This design eliminates unnecessary turbulence and shear stress associated with stirred tank reactors, paving the way for improved cellular viability and product yield. Continuous perfusion, integrated formulation for adherent cell differentiation, and automated counter-sedimentation for suspension cultures further enhance the platform's versatility.

Addressing Global Health Challenges

Yuyo Llamazares, CEO of Stämm, emphasized the pressing need for advancements in biomanufacturing technology. "Our goal with the HTB is to ensure that no patient, whether in Alaska, São Paulo, or Nairobi, has to wait for critical therapies due to centralized infrastructure limitations. We aim to close the logistical gap between scientific discovery and the swift availability of treatment options."

The global market for cell and gene therapy manufacturing has faced well-documented challenges due to centralized production infrastructure that demands significant capital investment. This approach does not align with the personalized, small-batch nature of advanced therapies. The modular and ready-to-use design of the HTB directly tackles these issues, replacing bulk stainless steel containers with easy-to-use, snap-in cartridges. This shift promises to shorten development timelines and expand manufacturing capabilities to underserved geographic areas, ultimately lowering the cost per patient for rare diseases and cell therapies.

Immediate Availability and Future Prospects

The HTB is currently available for process development in Research Use Only (RUO) applications. Pharmaceutical and biotechnology companies looking to evaluate Stämm's technologies for preclinical production, CAR-T therapy, stem cell expansion, or monoclonal antibody workflows are encouraged to reach out directly for collaboration opportunities.

Furthermore, comprehensive technical data review sessions are set to occur, and early access partnerships will be limited. This advancement in biomanufacturing heralds a new era where advanced therapies may become more accessible and efficient.

For more information, visit Stämm. A demonstration video showcasing the HTB can be viewed on their YouTube channel.